December 2006

CONTENTS

SHORT COMMUNICATIONS

Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier. Sébastien Bihorel, Gian Camenisch, Gerhard Gross, Michel Lemaire, and Jean-Michel Scherrmann .................................. 1945

Sulfinpyrazone C-Glucuronidation Is Catalyzed Selectively by Human UDP-Glucuronosyltransferase 1A9. Oranun Kerdpin, David J. Elliot, Peter I. Mackenzie, and John O. Miners .......... 1950

Identification of Binding Sites of Non-I-Helix Water Molecules in Mammalian Cytochromes P450. Charles W. Locuson and Timothy S. Tracy .... 1954

ARTICLES

Engineering of Cytochrome P450 3A4 for Enhanced Peroxide-Mediated Substrate Oxidation Using Directed Evolution and Site-Directed Mutagenesis. Santosh Kumar, Hong Liu, and James R. Halpert .......................................................... 1958

CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles. Vikas Kumar, Jan L. Wahlstrom, Dan A. Rock, Chad J. Warren, Lee A. Gorman, and Timothy S. Tracy .......................... 1966

Rapid Identification of P-glycoprotein Substrates and Inhibitors. Cheng Chang, Praveen M. Bahadur, James E. Polli, Peter W. Swaan, and Sean Ekins ........................................... 1976

CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-aminophenyl)furan- bis-O-methylami-


Comparative Metabolism and Disposition of Trichloroethylene in Cyp2e1−/− and Wild-Type Mice. Dojung Kim and Burhan I. Ghayyem ............ 2020


In Vivo Metabolism of L-Methionine in Mice: Evidence for Stereoselective Formation of...
Contents (cont’d.)

Methionine-d-Sulfoxide and Quantitation of Other Major Metabolites. JOSEPH T. DEVER AND ADNAN A. ELFARRA ............................................. 2036

Metabolic Aromatization of N-Alkyl-1,2,3,4-Tetrahydroquinoline Substructures to Quinolinium by Human Liver Microsomes and Horseradish Peroxidase. CHUNGANG GU, ROXANE COLLINS, DANIEL D. HOLSWORTH, GREGORY S. WALKER, AND RICHARD L. VOORMAN ............................................. 2044

Functional Analysis of Mouse and Monkey Multidrug Resistance-Associated Protein 2 (Mrp2). MIZUKI NINOMIYA, KOUSEI ITO, REMI HIRAMATSU, AND TOSHIHARU HORIE ............................................. 2056

Pharmacokinetics of Berberine and Its Main Metabolites in Conventional and Pseudo Germ-Free Rats Determined by Liquid Chromatography/Ion Trap Mass Spectrometry. FENG ZUO, NORIO NAKAMURA, TERUAKI AKAO, AND MASAO HATTORI ............................................. 2064

The Role of P-glycoprotein in the Bioactivation of Raloxifene. JAE H. CHANG, CHRISTOPHER J. KOCHANSKY, AND MAGANG SHOU ............................................. 2073

Drug-Metabolizing Enzyme Inhibition by Ketoconazole Does Not Reduce Interindividual Variability of CYP3A Activity as Measured by Oral Midazolam. MAYLEE CHEN, ANNE N. NAIZIGER, AND JOSEPH S. BERTINO, JR. ............................................. 2079

Comparison of Coumarin-Induced Toxicity between Sandwich-Cultured Primary Rat Hepatocytes and Rats in Vivo: A Toxicogenomics Approach. ANNE S. KIENHUIS, HELEEN M. WORTELBOER, JEAN-CHRISTOPHE HOFACK, EDWIN J. MOONEN, JOS C.S. KLEINJANS, BEN VAN OMMEN, JOOST H. M. VAN DELFT, AND ROB H. STIERUM ............................................. 2083

Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions. MARIO J. KARJALAINEN, PERTTI J. NEUVONEN, AND JANNE T. BACKMAN ............................................. 2091

Epirubicin Glucuronidation and UGT2B7 Developmental Expression. MATTHEW J. ZAYA, RONALD N. HINES, AND JEFFREY C. STEVENS ............................................. 2097

Structure-Activity Relationship and Elucidation of the Determinant Factor(s) Responsible for the Mechanism-Based Inactivation of Cytochrome P450 2B6 by Substituted Phenyl Diaziridines. YOSHIMASA KOBAYASHI, CHITRA SRIDAR, UTE M. KENT, SATISH G. PUPPALI, JOHN M. RIMOLDI, HAOMING ZHANG, LUCY WASKELL, AND PAUL F. HOLLENBERG ............................................. 2102

Peracetylation as a Means of Enhancing in Vitro Bioactivity and Bioavailability of Epigallocatechin-3-Gallate. JOSHUA D. LAMBERT, SHENGMIN SANG, JUNGIL HONG, SEO-JOO KWON, MAO-JUNG LEE, CHI-TANG HO, AND CHUNG S. YANG ............................................. 2111

ERRATUM


S Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Molecular model of human FMO3. See the article by Borbas et al. on page 1995 of this issue.